RheumatologyAdvisor (12/20, Khaja) reports, “Depression may impact psoriatic arthritis (PsA) treatment response and lead to higher rates of biologic disease-modifying antirheumatic drug (bDMARD) discontinuation, which may affect disease management and progression, according to study results published in Clinical Rheumatology.” In the study, “patients diagnosed with depression exhibited a notably elevated rate of treatment transitions attributed to lack of drug efficacy during the initial 12-month period.
Related Links:
— “Depression May Impact bDMARD Treatment Response and Discontinuation in Patients With Psoriatic Arthritis,” Hibah Khaja, Rheumatology Advisor , December 20, 2023